By using CD19 antibodies, such as inebilizumab, or blocking the interleukin-6 receptor signaling pathway, the number of CD19+ B cells can be reduced, and patients with NMOSD and MOG-AD may have fewer relapses. This evidence concerns the gene CD19 and Alzheimer disease.